Calcitonin gene-related peptide (CGRP)-targeted therapies have advanced migraine prevention, offering improved efficacy and tolerability compared to traditional treatments. However, a recent review highlights a paucity of data regarding the cardiovascular (CV) and cerebrovascular safety of these agents in patients with pre-existing vascular disease or recent vascular events.1
CGRP-targeted therapies, including monoclonal antibodies (mAbs) and gepants, represent a significant advancement in migraine prevention. These agents selectively inhibit the CGRP pathway, a key mediator in migraine pathophysiology, and are increasingly utilised, even as first-line options in selected patients.1 Clinical trials and real-world data generally suggest a favourable cardiovascular (CV) safety profile, particularly in patients without major risk factors.1
Cardiovascular and Cerebrovascular Safety Review
A narrative review published in Neurology in 2025 focused on the CV and cerebrovascular safety of CGRP-targeted migraine treatments.1 The review compared these newer agents with traditional migraine preventives and highlighted the limited evidence in specific high-risk patient populations.1
Concerns persist regarding the long-term effects and the safety of CGRP blockade in high-risk populations.1 The review specifically noted the paucity of data in patients with previous stroke, subarachnoid hemorrhage, myocardial infarction, or significant CV comorbidities.1 These populations have often been excluded from clinical trials, yet they are becoming increasingly important in clinical practice.1
The review also discussed the emerging topic of dual CGRP pathway blockade (mAbs plus gepants), noting that this has not previously been reviewed in the context of vascular risk.1 Based on the currently available scientific evidence, the authors offered structured clinical considerations to guide the use of CGRP-targeted therapies in patients with vascular risk or cerebrovascular disease.1 The aim was to support informed decision-making in a population where data is scarce.1
The review by Eller et al. underscores a critical gap in our understanding of CGRP inhibitor safety. While these agents are effective for migraine, the lack of robust data in patients with established vascular disease, such as prior stroke or myocardial infarction, means clinicians are largely operating on extrapolation rather than direct evidence. This situation places an undue burden on prescribers, who must weigh the benefits of migraine prevention against theoretical, yet unquantified, cardiovascular risks in a vulnerable population. Pharmaceutical companies developing these agents, like Amgen (erenumab), Eli Lilly (galcanezumab), Teva (fremanezumab), and AbbVie (ubrogepant, atogepant), have a responsibility to conduct post-market surveillance or dedicated trials in these high-risk groups to provide the necessary clarity. Without such data, the widespread adoption of CGRP inhibitors in patients with significant vascular comorbidities will remain a cautious, case-by-case decision.
For patients, this translates to a potential disparity in access to effective migraine prevention. Those with vascular risk factors may be denied CGRP inhibitors due to physician apprehension, or they may receive them without a full understanding of the long-term cardiovascular implications. This is particularly relevant given the increasing use of these agents, sometimes even as first-line options. The review's mention of dual CGRP pathway blockade further complicates the picture, as the safety profile of combining these agents in any population, let alone high-risk individuals, is largely unexplored. Guidelines bodies, such as NICE or the American Academy of Neurology, will struggle to provide definitive recommendations for these patient subgroups until more targeted research emerges.
Ultimately, the current evidence base necessitates a conservative approach. While CGRP inhibitors are a welcome addition to the migraine armamentarium, their use in patients with significant vascular risk factors should be approached with caution. Clinicians must engage in thorough risk-benefit discussions, acknowledging the limitations of current data. The onus is now on researchers and industry to address these evidence gaps, ensuring that effective migraine prevention can be safely extended to all who need it, regardless of their cardiovascular history.
- The Pivot CGRP inhibitors are increasingly used for migraine prevention, but their safety profile in patients with vascular risk factors is not fully established.
- The Data Evidence remains limited for CGRP-targeted therapies in patients with previous stroke, subarachnoid hemorrhage, myocardial infarction, or significant CV comorbidities.1
- The Action Clinicians should exercise caution and consider individual patient risk when prescribing CGRP inhibitors to those with established vascular disease, as data in this population is scarce.
ART-2026-096
Cite This Article
Team TLSFE. Cgrp inhibitors for migraine: cv safety data limited in high-risk patients. The Life Science Feed. Updated May 25, 2026. Accessed May 25, 2026. https://thelifesciencefeed.com/neurology/migraine-disorders/cgrp-inhibitors-for-migraine-cv-safety-data-limited-in-high-risk-patients.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Eller MT, Schwarzová K, Gufler L. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;104(2):e123-e134.